SCHEMBL29359679

SCHEMBL29359679

N#Cc1ccc2ccccc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.53
KCNH2 Q12809 1/20 0.53
NQO1 P15559 1/20 0.52
SOS2 Q07890 1/20 0.50
NCF1 P14598 3/20 0.46
CYP1A2 P05177 2/20 0.46
NOS2 P35228 1/20 0.46
BACE1 P56817 1/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
GAA P10253 1/20 0.46
TTR P02766 1/20 0.45
GLA P06280 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ACHE P22303 1/20 0.42
MGAM O43451 1/20 0.41
SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL75226 1.00 GRM5 (0.53) GRM5KCNH2NQO1SOS2NCF1
SCHEMBL27416745 1.00 GRM5 (0.53) GRM5KCNH2NQO1SOS2NCF1
Methane SCHEMBL27560165 0.98 GRM5 (0.52) GRM5KCNH2NQO1SOS2NCF1
Hydrochloric Acid SCHEMBL28328423 0.98 GRM5 (0.52) GRM5KCNH2NQO1SOS2NCF1
Hydrazine SCHEMBL28226443 0.96 GRM5 (0.50) GRM5KCNH2NQO1SOS2NCF1
Ethane SCHEMBL28069598 0.96 NQO1 (0.53) GRM5KCNH2NQO1SOS2NCF1
Ethylene SCHEMBL4594450 0.96 GRM5 (0.50) GRM5KCNH2NQO1SOS2NCF1
SCHEMBL15877631 0.89 GRM5 (0.62) GRM5KCNH2NQO1SOS2NCF1
Quinoline SCHEMBL28130812 0.89 ALDH1A1 (0.61) GRM5KCNH2NQO1SOS2NCF1
Pyrrole SCHEMBL28298992 0.89 GRM5 (0.45) GRM5KCNH2NQO1SOS2NCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3386511-B2 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-03-20 EP claimed
EP-4649139-A1 METHODS FOR EXPANDING IMMUNE CELLS AND RELATED COMPOSITIONS AND USES THEREOF Nkarta, Inc. (US) 2025-11-19 EP disclosed
WO-2025011623-A1 CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海壹迪生物技术有限公司 2025-01-16 WO disclosed
US-12172965-B2 Drug conjugate comprising quinoline derivatives Universite Paris-Saclay (FR) 2024-12-24 US disclosed
CN-119019327-A Acetylation method of quinoline or isoquinoline compounds 常州工程职业技术学院 2024-11-26 CN disclosed
WO-2024163619-A1 METHODS FOR EXPANDING IMMUNE CELLS AND RELATED COMPOSITIONS AND USES THEREOF NKARTA, INC. (US) 2024-08-08 WO disclosed
CN-112710838-B Application of quinoline nitrile derivative in detection of protein by protein imprinting method and preparation method thereof 华东理工大学 2024-08-06 CN disclosed
EP-3853208-B1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES CENTRE NAT RECH SCIENT (FR) 2023-06-07 EP disclosed
US-11638706-B2 Methods for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-05-02 US disclosed
US-11608501-B2 Methods for modifying RNA splicing PTC THERAPEUTICS, INC. (US) 2023-03-21 US disclosed
US-20220023435-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES Universite Paris-Saclay (FR) 2022-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023435-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES HRH3, ABCC3, ORC3 GRM5 2140/4885KCNH2 1051/4885NQO1 98/4885
US-11608501-B2 Methods for modifying RNA splicing RBM17, SNRPA1, SNRPE GRM5 2805/4885KCNH2 4351/4885NQO1 2738/4885
US-12172965-B2 Drug conjugate comprising quinoline derivatives HRH3, ABCC3, ORC3 GRM5 2140/4885KCNH2 1051/4885NQO1 98/4885
US-11638706-B2 Methods for treating Huntington's disease HTT, HYPK, FH GRM5 256/4885KCNH2 2233/4885NQO1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.